



Third Congress of the Asia-Pacific Council on Contraception

Beijing, China

11-13 Jun 2010

**Prof. Madya Nik Hazlina Nik Hussain
Unit Perkembangan Kesihatan Wanita, PPSP**

Tidak hadir kerana kehabisan masa / percuti



APCO
ASIA PACIFIC COUNCIL ON
CONTRACEPTION



THE 3RD APCOC CONGRESS 2010, BEIJING

亚太避孕理事会第三届国际会议
2010,北京






TABLE OF CONTENTS

| | Page |
|-----------------------------------|------|
| Timetable | 5 |
| Welcome Note | 6 |
| Committee | 7 |
| Sponsors | 8 |
| General Information | 9 |
| Opening Remarks | 11 |
| First APCOC Lecture 2010 | 13 |
| Scientific Program | 14 |
| Topics of Breakfast Meeting | 18 |
| List of Poster Boards | 19 |
| Abstracts | 23 |
| Invited Speakers | 24 |
| Oral Presentations | 31 |
| Poster Presentations | 36 |
| Index | 57 |



TIMETABLE

| TIME | FRIDAY JUNE 11, 2010 | | | SATURDAY JUNE 12, 2010 | | | SUNDAY JUNE 13, 2010 | | |
|-------------|---|-------------------------------------|--|--|---|--------------------------------------|---|--|--|
| 08:00-09:00 | Registration | | | Session 7: Meet the experts@ breakfast (Multifunctional Hall, First Floor) | | | Session 14: Meet the experts@breakfast (Multifunctional Hall, First Floor) | | |
| 09:00-10:30 | Session 1: Plenary Opening ceremony APCOC lecture (Room 309) | | | Session 8: Plenary "New evidence on safe use" (Room 309) | | | Session 15: Debate Should OC be made available without prescription? (Room 309) | | |
| 10:30-11:00 | Coffee break / Exhibition Hall | | | | | | | | |
| 11:00-12:00 | Session 2: MSD Symposium "Contraception in the consumer age" (Room 309) | | | Session 9: Bayer Symposium "Innovation and new developments: expanding benefits beyond oral contraception" (Room 309) | | | Session 16: Symposium "Reproductive and sexual health in the young" (Room 309) | | |
| 12:30-13:30 | Session 3: Zizhu Symposium / Lunch break (Room 309) | | | Lunch break (Room 309) | | | Closing | | |
| 13:30-15:00 | Session 4: Bayer Symposium "Mirena® a contraceptive solution for the forward looking woman" (Room 309) | | | Session 10: MSD Symposium "Changing Asia and contraception" (Room 309) | | | | | |
| 15:00-15:30 | Coffee break / Exhibition Hall | | | | | | | | |
| 15:30-17:00 | Session 5a: Concurrent "Dealing with continuation of use" (Room 309) | | Session 5b: Concurrent "What is new in contraception use" (Room 311) | | Session 11a: Concurrent Free Communication (Room 309) | | Session 11b: Concurrent Free Communication (Room 311) | | |
| 17:00-18:00 | Session 6a: Interactive Case studies (Room 309) | Session 6b: Workshop1 (Room 311) | Session 6c: Workshop2 (Room 402) | Session 12a: Interactive Case studies (Room 309) | Session 12b: Workshop1 (Room 311) | Session 12c: Workshop2 (Room 402) | | | |
| 19:00 | Private activity | | | Session 13: Welcome reception Keynote address: Prof. Wang Yifei Presentation of certificates Dinner (Banquet Hall C) | | | | | |

The Third Congress of the Asia-Pacific Council on Contraception (APCOC)
Better contraception for better life

WELCOME NOTE

AN INVITATION TO THE CONGRESS

Dear friends and colleagues,

The Asia-Pacific Council on Contraception (APCOC) wishes to invite you to our Third Congress in Beijing. This event follows from the success of our First Congress as a 1-day scientific symposium in Shanghai in November 8, 2007 and our 2½ day Second Congress in Macau in December 4-6, 2008.

With a strong mission "to promote safe and effective contraception in planning families for the Asia-Pacific region and beyond", APCOC will present up-to-date and relevant scientific information as part of its educational program. For this Congress, we will discuss a wide range of topics including suitability of new and current contraceptive methods for the diverse needs in the region and ways to cope with the emerging problems of unplanned pregnancy, abortions and sexual health among young people. We have invited recognised authorities in the field to discuss new evidence on safe use of hormonal and non-hormonal methods.

In order to encourage and involve delegate participation, the program consists of different presentation formats like workshops, meet the experts @ breakfast, interactive case studies and free communications – in addition to the conventional plenary session and symposium. A highlight of the Congress is the debate, with two experienced clinicians giving their views on a very relevant and important question: "should OC be made available without prescription?" and delegates will be polled before and after the debate to see how convincing are their views.

A Congress which brings together colleagues from different parts of Asia-Pacific region and the rest of the world will not be complete or successful without its ability to allow delegates to meet each other and develop meaningful networking for the future. We hope all delegates will take advantage of the opportunity.

As you will see in the scientific program, all Directors of the APCOC Board have a busy and active role in bringing this educational event to the region. In particular, the organising committee has worked very hard to ensure a stimulating, interesting and useful experience for all delegates in the beautiful city of Beijing, greatly enhanced by the most recent Olympic Games.

| | |
|--|--|
| Professor Soo Keat Khoo Chair, APCOC | Professor Wu Shangchun Chair, Organising Committee |
| Dr. Dominic Fuk-Him Li Organising Committee and Treasurer, APCOC | Professor Cheng Linan Organising Committee and Chair, Family Planning in China |

In collaboration with the National Research Institute of Family Planning, Beijing.

COMMITTEE



Biran Affandi
(Jakarta)



Luu Hong Thi
(Hanoi)



Dominic F-H Li
(Hong Kong)



Soo Keat Khoo
(Brisbane)



P C Wong
(Singapore)



Surasak
Taneepanichskul
(Bangkok)



Wu Shangchun
(Beijing)



Cheng Linan
(Shanghai)



ASIA PACIFIC
COUNCIL ON
CONTRACEPTION.



Enrico Oblepias
(Manila)



Im Soon Lee
(Seoul)



Chem Jye Jeng
(Taipei)



Jamiyah Hassan
(Kuala Lumpur)

EXECUTIVE GROUP

Professor Soo Keat Khoo (Chair)
Professor S Taneepanichskul (Secretary)

Professor P C Wong (Co-Chair)
Dr. Dominic Fuk-Him Li (Treasurer)

ORGANISING COMMITTEE

Professor Wu Shangchun (Chair)
Dr. Dominic Fuk-Him Li (Finance)

Professor Cheng Linan (Co-Chair)

CO-ORGANISER

(NATIONAL RESEARCH INSTITUTE FOR FAMILY PLANNING)

Mr. Fu Wei
Professor Jia Mengchun

Ms. Liu Qing

SPONSORS



Bayer HealthCare
Bayer Schering Pharma

Building on more than 80 years of expertise, Bayer Schering Pharma is the leading provider in women's healthcare today. We focus on three key areas: contraception, menopause management and gynecological therapies.

Hormonal contraception

Bayer Schering Pharma is the global market leader in the field of hormonal contraception. Our innovative contraceptives enable women to make a conscious decision on the size of their families. We offer a wide range of products to suit women's individual needs. This includes low-dose contraceptives with additional health benefits. Our portfolio also includes a hormone-releasing intrauterine contraceptive which offers convenient, reversible contraception for up to five years.

Menopause management & Gynecological therapies

Menopause is associated with a decline in female hormone production. In this life phase, many women experience symptoms – including hot flushes, night sweats and sleeping disorders – that may significantly impair their quality of life. Bayer Schering Pharma offers therapies which alleviate menopausal complaints quickly and effectively.

We are also developing new treatment options for gynecological diseases with a high unmet medical need. These include menstrual disorders, painful periods, endometriosis and uterine fibroids.

Bayer (South East Asia) Pte Ltd

63 Chulia Street; OCBC Centre East, 14th floor, Singapore 049514

Website: www.bayerhealthcare.com

Tel: +65 64961497



Today's Merck is working to help the world be well. Through our medicines, vaccines, biologic therapies, consumer and animal products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching programs that donate and deliver our products to the people who need them. Merck. Be well. For more information, visit www.merck.com.

Hangzhou MSD Pharmaceutical Co. Ltd. - Shanghai Representative Office

20F Park place 1601 NanJing road(West) Jingan Diatrict Shanghai 200040,China

Website: www.merck.com.

Tel: +86 021 2211-8888

Fax: +86 021 2211-8899



紫竹药业

ZIZHU PHARMACEUTICAL

Beijing Zizhu Pharmaceutical Co., Ltd. (BZP) is a large state-owned pharmaceutical company under Beijing Pharmaceutical Group. It is a development and production base for family planning medicines and reproductive health medicines, and a designated manufacturer for contraceptives. BZP is one of enterprises in China that first obtained GMP certificates. Its main products include emergency contraceptive Yuting ® (levonorgestrel 0.75mg, 1.5mg), anti-early pregnancy medicine Mifepristone, the third generation of daily oral contraceptive Compound Gestodene Tablets, Gestrinone and Zizhu Aiwei ® (Tibolone Tablets 2.5mg), etc.

Beijing Zizhu Pharmaceutical Management Co., Ltd (BZPM)

Website: <http://www.zizhu-pharm.com.cn>

Tel: 010-62263727 / 010-62241908

010-62250847 (Foreign Trade Department)

GENERAL INFORMATION

VENUE: China National Convention Center. www.cncchina.com


WEATHER: Early summer is the best season in Beijing. The weather in June is nice and a bit dry with the average daily temperature of 36°C.

LANGUAGE: English is the official language of the Congress and there will be simultaneous translation into Chinese.


INSURANCE AND LIABILITY: The Congress Secretariat and the organizers cannot accept liability for personal accidents, nor for loss of, or damage to private property of delegates. Delegates should make their own arrangements with respect to health and travel insurance.

CURRENCY EXCHANGE: In China, only RMB is used. Exchange centers can be found at airports, hotels and tourist shopping centers. The rate of exchange is set by the Bank of China, which is now about US\$ 1.00 = RMB 6.82. Visa, Master, American Express, Diners Club and JCB are accepted in many department stores and hotels.

EVENT ORGANIZER: Image Star PR Consulting Co.,Ltd. As the most eye attracting PR company in the industry, Image Star is well known for her high profile platform and performance. The team has been continuously serving Fortune Top 500 companies. We, with our outstanding creativity and proficient execution, have been helping the clients with their brand promotion and product marketing plan. Our efforts have been extremely helpful for the clients keeping the leading position in the industry.



- 1 国家会议中心
China National Convention Center
- 2 国家会议中心大酒店
China National Convention Center
Grand Hotel
- 3 北京北辰洲际酒店
Intercontinental Beijing Beichen



中国2010年上海世博会医药全球合作伙伴
Pharmaceutical Global Partner of Expo 2010 Shanghai China

The Third Congress of the Asia-Pacific Council on Contraception (APCOC)
Better contraception for better life

Mifolian[®]

MIFEPRISTONE TABLETS 200mg

Official Partner of the Third Congress of the Asia-Pacific Council on Contraception

The only API manufacturer of this product approved by US FDA

Assigned Research Product of World Health Organization

A product for emphasized spreading in Chinese Medical Association



Shanghai Pharmaceutical (Group) Co., Ltd.
SPH成员 New Hualian Pharmaceutical Factory

Site Address: 217 Minle Road, Shanghai China
Tel: +86-21-57503293
Fax: +86-21-57502671

Sales Dept.: Building A, No.494 Zhongxing Road, Shanghai, China
Tel: +86-21-51069532
Fax: +86-21-51069531

OPENING REMARKS

DISTINGUISHED GUESTS, FRIENDS AND COLLEAGUES,

May I greet you all with a very good morning,

On behalf of the Board of Directors and the Organising Committee, I extend a warm welcome and hope you have travelled well – and that you are ready for an exciting 2½ days of conference.

We welcome you to the APCOC Congress. This is the third educational event since APCOC was founded in late 2006 – the first Congress was in Shanghai in 2007, and the second Congress was in Macau in 2008. We did not have one in 2009 because of the global financial crisis; this enabled us to accumulate resources to make this Congress a better one. For that, I wish to acknowledge the generous support of our sponsors: Bayer Schering Pharma as Platinum Sponsor, MSD Technologies as Gold Sponsor, Zizhu Pharmaceuticals as Silver Sponsor, and Ai Mu, Da Hua and Hua Lian.

We welcome you to Beijing, the capital city of the most populated country on Earth – the People's Republic of China – a city of old and new charms, greatly enhanced by the flow-on from the recent Olympic Games.

We welcome you to the China National Convention Centre – this is a purpose-built conference building which provides us with a friendly environment for our intellectual discourse.

We also welcome you to know us better as a non-profit professional organisation. Our mission is "to promote safe and effective contraception in the planning of families for Asia-Pacific region", and I would also like to introduce to you two important elements in APCOC.

This shows the membership of the Board of Directors – we are drawn from 12 cities in the region. We accept the responsibility to use our professional expertise to improve the quality of life of the people through sound family planning.

This shows the focus of APCOC. In order to meet the diverse needs of the people, our strategy is to link our objectives of effective education, advocacy and promotion of best practice with the expectations of choice, improved health benefits and freedom for the people to lead a better life.

The theme of this Congress is "Better contraception for better life". This will be the topic for our Keynote Address by Professor Yifei Wang. Professor Wang is well-known in China and the world as a leader in family planning and reproductive health. We look forward to his lecture at the Welcome Reception/Dinner on the evening of day two.

When we discussed the theme for this Congress, there are several drivers which make it most appropriate for our modern society.

"Contraception" – as practised now – is certainly "better" in many ways. There is a wide range of contraceptive methods, in particular, those based on the steroid hormones. Hormonal contraception has revolutionised the practice of family planning throughout the world. The discovery that steroid hormones can effectively prevent pregnancy – acting on several mechanisms in the reproductive system – has given us a very high degree of reliability. Non-hormonal methods have not kept pace with such advancement as in hormonal methods. However, cost remains a large impediment to wider usage. At this stage in the development of "better contraception", access and acceptability become issues which need to be addressed by all stakeholders.

If 'better' means safer, then we are witnessing a positive change for reducing adverse events, with lower doses and improved steroid molecules. Recent research supports the fact that modern contraceptive methods have a better safety profile, especially in vascular complications. Unfortunately, despite reassuring evidence of safety, there remain misperceptions and myths which make potential users hesitant to use the method. This apparent concern is often heightened and promulgated by unfriendly media which attempt to represent minority, self-interest groups. Another important reason that "safety" is an issue is the failure to recognise that there are contraindications, and that some unhealthy women should not use hormonal contraception because of their inherent predisposition, like to embolism. It becomes the responsibility of education to inform both the healthcare provider and the consumer.

If contraception is "for better life", we have yet to reach this worthwhile goal in many social settings, particularly among the poor and the uneducated. Family planning refers not only to limiting family size but also spacing of pregnancies. We know that poverty is often associated with large families, and such large families reduce opportunities to achieve a "better life" – as in improving living standards. We need to develop effective strategies for the less informed, less privileged and less accessible groups in our society. We need to encourage sexual responsibility at the beginning of sexual activity and to equip young people with the means to avoid unplanned pregnancy. The key is sound education. We need to prepare our young people for healthy sexuality and relationships.

As delegates to the Congress, you will have these issues addressed. You are encouraged to participate actively in the discussion. We have provided different educational formats like workshops, meet the experts @ breakfast, free communications, debate and interactive case studies to suit all of you.

I wish you an enjoyable and rewarding Congress.

FIRST APCOC LECTURE 2010

**"NEED, CHALLENGES AND STRATEGIES IN
MODERN CONTRACEPTIVE PRACTICE"**

Professor Soo-Keat Khoo

Chair, Asia-Pacific Council on Contraception and Head, Obstetrics & Gynaecology, University of Queensland,
Director, Betty Byrne Henderson Women's Health Research Centre, Royal Brisbane and Women's Hospital, Brisbane Australia

A short version

World population growth is estimated to reach 8,919 billion by 2050 – and in that period of 40 years, at least another 2.6 billion couples will require contraception. In the Asia-Pacific region, the fertility rate is found to be high in those countries where life expectancy is low; and vice versa. Therefore, there appears to be a need for use of contraception, "to enhance the health of women and change the world for the better" (as stated by Malcolm Potts). Modern contraception is nearly 100 years old, purported to begin when Margaret Sanger opened the first family planning clinic in 1916 in USA. From that time, we have come to appreciate the tremendous impact of contraception on the population as well as on the individual – bringing a range of benefits to improve quality of life.

However, utilisation continues to be hindered by myths and lack of knowledge – and this is evident by a high incidence of unplanned pregnancies and sexually-transmitted diseases among young people around the world. In the "Talking sex and contraception" survey of young people aged 15-19, "two-thirds are found not informed about contraception, nearly half have started sexual activity without using adequate contraception, and nearly all of them welcome better education on sexuality and sexual behaviour".

The need to educate young people in sexuality, sexual responsibility and behaviour has been identified by APCOC as an important initiative. APCOC has developed a "Train-the-Trainer" toolkit – a booklet and its companion slide deck. This resource in English can be translated into other languages and modified to suit cultural differences. This toolkit will be available to teachers and educators involved in teaching school children and young adults about sexual development, behaviour and responsibility. The novelty of the APCOC toolkit is that the presented material covers 4 components (human development, relationships, sexual behaviour, and sexual health) and is made appropriate for the child's own stage of development and understanding in 3 modules (Level 1 for youths aged 10-13, Level 2 for adolescents aged 14-17, and Level 3 for young adults aged 18-21).

In modern living, women, in general, face many influences and new challenges as they try to balance career, lifestyle and family. We need to be aware that these women are looking at contraception in a totally different context – with emphasis on ease of use, reversibility and other additional benefits. For women who are less exposed to modern society and living in rural and remote settings, there are also many but different factors which influence their likelihood to use contraception – the most important factors, according to a recent study in Indonesia (2008), are the "ideal" number of children and the number of living children, socioeconomic status and exposure to family planning messages. However, access is still an issue.

The method which has revolutionised contraceptive practice is, without doubt, the Pill. The Pill is now 50 years old, and the modern Pill – as we know it today – is very different with dose reduction, phasing and sequencing, steroid hormones with new profiles, and new routes of administration. The Time Magazine in its May 2010 edition describes the achievements of the Pill as: "So small. So powerful. An so misunderstood". A part of this ongoing misunderstanding is the question of safety. Public concern, scientific enquiry and media attention have kept a watching brief on this issue. It is, therefore, reassuring to be informed by the largest and longest longitudinal study on the use of the Pill that the mortality rate of Pill-users is not compromised. In fact, the Royal College of General Practitioners' study reported that the risk of death of ever-users of the Pill is significantly less than that of never-users – the risk is reduced by 12% for all causes, for all cancers by 15% and for all circulatory diseases by 14%.

There is also the concern about the link to cancer, a phobia which has deterred some women from use. New studies have confirmed no link to breast cancer, reduced risk for uterine and ovarian cancer, and a questionable increased risk for cervical cancer which is also associated with sexual activity and human papillomavirus (HPV). The evidence showing no increased risk of breast cancer in Pill-users is now very strong – four large studies found no link, regardless of age of the user. The evidence showing a reduced risk of ovarian cancer in Pill-users is also very strong but less known to the public. Pooled data from 45 studies (23,000 users and 87,000 controls) found the relative risk to be 0.73; this reduction is nearly 30% persisting for more than 30 years after stopping, and that this risk is further reduced to 50% for long-term users. Through this effect, the Pill is able to offer far-reaching health benefits to women who choose to use it, because ovarian cancer has a very high mortality rate. In absolute terms, 10 years of Pill-use is predicted to reduce the incidence of ovarian cancer by 4 per 1,000 from (12 to 8) and deaths by 2 per 1,000 (from 7 to 5). With current prevalence of the disease, the world-wide impact can be as high 200,000 less ovarian cancer and 100,000 less deaths per year.

Since its beginning – in the 1900's – modern contraceptive practice has made a major contribution to women's well-being, giving her the freedom to control her fertility and to cope with new challenges in her life. However, more effort is required to address issues of accessibility and acceptability in the next 25 years.

SCIENTIFIC PROGRAM

DAY 1 - FRIDAY, JUNE 11, 2010

| | | | |
|-------------|--|--|--|
| 08:00-09:00 | Registration | | |
| 09:00-10:30 | Session 1: Plenary / Opening ceremony / APCOC lecture "Contraception: needs, challenges and strategies – APCOC's mission and initiatives" – Soo Keat Khoo | | (Room 309) |
| 10:30-11:00 | Coffee break | | (Exhibition Hall) |
| 11:00-12:30 | Session 2: Sponsored symposium (MSD Technology Pte) Chair: P C Wong "Contraception in the consumer age" <ul style="list-style-type: none"> • <i>Modern women, modern lives</i> Jean-Michel Foidart • <i>Myths and misconceptions about contraception</i> Diana Mansour • <i>Too much or too little: a woman's concern for E</i> Jean-Michel Foidart • <i>Contraception over long term (Implanon)</i> Hans Reker | | (Room 309) |
| 12:30-13:30 | Session 3: Sponsored symposium (Zizhu Pharmaceutical) / Lunch break Chair: Cheng Linan Speaker: Wu Shangchun | | (Room 309) |
| 13:30-15:00 | Session 4: Sponsored symposium (Bayer HealthCare) Chair: Jamiyah Hassan, Yu Qi "Mirena® a contraceptive solution for the forward looking woman" <ul style="list-style-type: none"> • <i>Mirena® a contraceptive fit suitable for women at all stages of reproductive life</i> Diana Mansour • <i>Mirena® an alternative to surgical intervention</i> Sihyun Cho • <i>Mirena® insertion and counselling from a patient perspective</i> Harlina Halizah Hj Siraj | | (Room 309) |
| 15:00-15:30 | Coffee break | | (Exhibition Hall) |
| 15:30-17:00 | Session 5a: Concurrent symposium (Room 309) Chair: Chergng Jye Jeng, Seok Hyun Kim "Dealing with continuation of use" <ul style="list-style-type: none"> • How to deal with side-effects in hormonal contraception Lee Shulman (Chicago) Cover: oral, intra-uterine, transdermal, subcutaneous, vaginal • What are the ways to encourage compliance Christine Read (Sydney) Cover: oral, IUD, Mirena, condom • How to increase access to contraceptive use – a low-cost implant Marcus Steiner (USA) Cover: various methods | Session 5b: Concurrent symposium (Room 311) Chair: Biran Affandi, S Taneepanichskul "What is new in contraception use" <ul style="list-style-type: none"> • New products: now and the future Maureen Cronin (Berlin) Cover: range, mechanism, benefits/risks • Development of intrauterine contraception Wu Shangchun (APCOC) Cover: current status and what is new in China? • Status of male contraception Gu Yiqun (Beijing) Cover: Mechanism, products other than condom, experience in China | |
| | Session 6a: Interactive case studies (Room 309) Soo Keat Khoo Alfred Mueck, Christine Read Cover: difficult clinical problems and step-by-step solving commentary and discussion | Session 6b: Workshop (Room 311) Enrico Oblepias, Kuldip Singh "Evidence-based best practice in contraception" | Session 6c: Workshop (Room 402) S Taneepanichskul Doo Seok Choi "Non-contraceptive uses – benefits and what conditions" |
| 17:00-18:00 | | | |

The Third Congress of the Asia-Pacific Council on Contraception (APCOC)
Better contraception for better life

DAY 2 - SATURDAY, JUNE 12, 2010

| | | | |
|-------------|---|---|--|
| 08:00-08:45 | Session 7: Breakfast / Meet the experts for 20 topics discussion Convenors: Biran Affandi, Cherng Jye Jeng | | (Multifunctional Hall, First Floor) |
| 09:00-10:30 | Session 8: Plenary Chair: Im-Soon Lee, Jamiyah Hassan "New evidence on safe use" <ul style="list-style-type: none"> Hormonal contraception and vascular effects Cover: venous and arterial effects, geographic, ethnic differences, impact of age/lifestyle, steroid components/doses Hormones and cancer re-visited Cover: new evidence, reduced steroid doses, prevention | | (Room 309) |
| 10:30-11:00 | Coffee break | | (Exhibition Hall) |
| 11:00-12:30 | Session 9: Sponsored symposium (Bayer HealthCare) Chair: Dominic Fuk-Him Li, Hong Kyoan Lee "Innovation and new developments: expanding benefits beyond oral contraception" <ul style="list-style-type: none"> Modern contraception for the modern women Introducing a new class of oral contraceptive | | (Room 309) |
| 12:30-13:30 | Lunch break | | (Room 309) |
| 13:30-15:00 | Session 10: Sponsored symposium (MSD Technology Pte) Chair: Biran Affandi, Li Jian "Changing Asia and contraception" <ul style="list-style-type: none"> New demands, new approach Contraception and counselling Contraception counselling – a China perspective | | (Room 309) |
| 15:00-15:30 | Coffee break | | (Exhibition Hall) |
| 15:30-17:00 | Session 11a: Concurrent session (Room 309) Chair: Enrico Oblepias, Sun Haeng Kim <ul style="list-style-type: none"> The effects of levonorgestrel-releasing intrauterine device (Mirena®) on adenomyosis Chul Kim Clinical efficacy of levonorgestrel-releasing Intrauterine system (Mirena) in women with abnormal uterine bleeding Eun Chan Park An investigation on "frameless GyneFix" IUD: a retrospective survey of 24,336 women for 5 years Hao Mingli Multicenter randomized controlled clinical trial of γ-IUD (memory alloy) Liu Xiaoi Continuation rates/removal Implanon users (Select 1 best out of 5) Hyeon Chul Kim | Session 11b: Concurrent session (Room 311) Chair: Jamiyah Hassan, Dominic Fuk-Him Li <ul style="list-style-type: none"> Effects of sex hormones in oral contraceptives on the Female Sexual Function Score: A study in German female medical students Alfred O Mueck Safety aspects of dienogest in endometriosis; pooled data from a clinical development program Jeff Hassall Ethinylestradiol 20mcg/drospirenone 3mg combined oral contraceptive in 24/4 regimen in premenstrual dysphoric disorder: a randomized, multicenter, double-blind, parallel study Joachim Marr Different risk of breast cancer due to different progestogen action? New insight on proliferative mechanism Rong Chen Infants outcomes after levonorgestrel-only emergency contraception failure; a prospective cohort study (Select 1 best out of 5) Zhang Lin | |
| | Session 12a: Interactive case studies (Room 309) Soo Keat Khoo Lee Shulman, Byung Seok Lee Cover: difficult clinical problems and step-by-step solving commentary and discussion | Session 12b: Workshop (Room 311) Cheng Linan Damrong Reinprayoon Cover: Post-abortion contraception | Session 12c: Workshop (Room 402) Biran Affandi Soon Ki Hong Cover: Contraception for special conditions |
| 17:00-18:00 | | | |
| 19:00-21:00 | Session 13: Welcome Reception/Educational Evening MC: P C Wong Keynote address "Better contraceptive service and reproductive health, better social development and quality of life"(Wang Yifei – Shanghai) Introduction: Wu Shangchun Presentation of sponsorship plaques and certificates. Dinner and entertainment | | (Banquet Hall C) |

The Third Congress of the Asia-Pacific Council on Contraception (APCOC)
Better contraception for better life

DAY 3 - SUNDAY, JUNE 13, 2010

| | | |
|-------------|--|-------------------------------------|
| 08:00-08:45 | Session 14: Breakfast / Meet the experts for 20 topics discussion Convenors: Biran Affandi, Cherg Jye Jeng | (Multifunctional Hall, First Floor) |
| 09:00-10:30 | Session 15: Debate: Should OC be made available without prescription? Moderator: PC Wong Voting system: pre-debate and post-debate poll Yes: Lee Shulman No: Christine Read | (Room 309) |
| 10:30-11:00 | Coffee break | (Exhibition Hall) |
| 11:00-12:30 | Session 16: Symposium Chair: Cherg Jye Jeng, Enrico Oblepias "Reproductive and sexual health in the young" <ul style="list-style-type: none"> Adolescent sexuality and sexual behaviour (experience in Asia-Pacific region) Jeong Jae Lee (Seoul) Sexual health and risk of sex-related infections (screening and management) Kamhaeng Chaturachinda (Bangkok) Evolving needs and influences on contraceptive use in young people Kuldip Singh (Singapore) | (Room 309) |
| 12:30 | Closing | |

家庭医生在线

www.j10l.com

公司简介:

公司旗下的家庭医生在线网www.j10l.com, 创办于1998年, 是全国最具品牌价值的健康网站之一。

- 2000年, 被新华社评为“中国五大健康网站”;
- 2008年10月, 被国家新闻出版总署中国出版科学研究所和中国出版工作者协会评为“全国期刊社网站10强”;
- 2009年7月, 在国家新闻出版总署主管的“第三届中国数字出版博览会”上, 荣获全国数字出版“知名品牌”奖和“优秀作品”奖两个奖项。
- 2009年9月, 获得国家新闻出版总署颁发的“互联网出版许可证”, 获准从事互联网杂志、互联网音像出版、手机出版等互联网信息服务业务。这是迄今为止获得“互联网出版许可证”的全国极少数健康网站之一。

《家庭医生E刊》系列电子杂志 ▶ ▶ ▶

《家庭医生E刊》系列电子杂志由家庭医生在线独立制作, 包含了《家庭医生E刊》、《家庭医生E-Lady》、《家庭医生E-Man》、《家庭医生E-Baby》四个系列, 按周轮流出版。它吸收了平面媒体和网络媒体的双重优点, 除了坚持家庭医生“科学性、趣味性、实用性、新颖性”四性合一的传统风格外, 内容和表现形式更加时尚。《家庭医生E刊》系列电子杂志的发布渠道囊括了新浪、腾讯、Xplus、Zcom、博享、麦客、读客、中国商榜网、独揽天下、众志传媒等国内几乎所有的知名电子杂志发布平台, 受众广泛, 目前最高单期发行量已经超过1000万, 月发行量在全国健康类电子杂志中排在第一位, 同时也进入了全国所有各类电子杂志的前十名。2009年7月, 《家庭医生E刊》系列电子杂志因其出色的表现, 荣获国家新闻出版总署主管的全国数字出版“优秀作品”奖。



AiMu's New Products Have Been Launched

Medical Device Advertising (text) Permit
Number 2010030005 by Liaoning FDA

Tips: These products should be inserted at medical
organizations. Contraindication or notices see instructions.



AI MU

AiMu Brand Intrauterine Device



AiMu MCuII Functional Intrauterine Device (New)
Medical Device Production Permit Number 3460756 of
2009 by State FDA



AiMu MYCu Intrauterine Device (New)
Medical Device Production Permit Number 3461002 of
2009 by State FDA

Low Expulsion Rate

Memory alloy support is not easy to deform
in the uterine cavity. Shape designed according
to the form of the uterus and dynamic
mechanism, which makes it not easy to translocate
and expulse.

Low Pregnancy Rate with IUD

Sends effective contraceptive
substance to the high, middle,
and low position of the uterine
cavity, hence better serves its
contraceptive function.

Easy and Convenient Insertion and Removal

Inserted by means of withdrawal,
which is easy and convenient. Strong
sense of metal friction between probe
and IUD's lower edge at the time of
removal, which makes accurate positioning
and extractor easy to operate.
Easy and convenient rechecking by
means of B ultrasonic wave or X-rays
after insertion of IUD.

Slight Side Effects

With a copper surface area of 225mm²,
it has little stimulation to the endometrium.
With indomethacin in the side arms, it releases
indomethacin to decrease the synthesis
of prostaglandin, hence reduces the side effects
of bleeding and pain.

Long Life

Both AiMu MCuII IUD and MYCu
IUD could remain in the uterus for
15 years.

Retrograde Infection Prevention

Without tail filament, the possibility
of retrograde infection is extinguished
and men's discomfort caused by it is
eliminated.



LIAONING AIMU MEDICAL SCIENCE & TECHNOLOGY CO., LTD

Registered (production) Address: No.195 Linqing Street, Anshan New Hi-Tech
Industrial Development Zone (East Compound), Liaoning Province, China
Tel: 0412-5217998, 5217988, 5211138 Fax: 0412-5216508 Post Code: 114044
Web Site: www.aimu.com.cn E-mail: aimu@aimu.com.cn aimuiud@163.com

TOPICS OF BREAKFAST MEETING

1. Explaining new options to Chinese Women
2. The reason women seek our advice
3. Contraception: Implanon versus IUD
4. Non-contraceptive benefits/risks in oral contraception
5. Contraception for women with pre-menstrual syndrome/dysphoric disorder
6. Long-acting methods (injectable, implant, intrauterine)
7. Importance of progestogen component in combined preparations
8. Non-oral hormonal contraception (patch, vaginal rings, subcutaneous implants)
9. Contraception for the postpartum woman
10. Contraception for the woman after abortion
11. Contraception and breast cancer (personal history, family history, risk factors)
12. Contraception and risk of vascular disease (venous, arterial, other risk factors, smoking, age)
13. Contraception and the adolescent girl (methods, compliance, risk of sexually-transmitted infection, legal status)
14. Contraception and risk of weight gain (true/false, predisposition, fat distribution, other factors)
15. Choice of contraception for the woman with androgenicity (acne, hirsutes)
16. Emergency contraception (methods, availability, educational support)
17. Use of evidence to answer questions in contraception (myths, misperceptions, personal bias, media reporting)
18. Contraception for women over the age of 40 (predisposition, risk factors, benefits, special needs)
19. Contraception and sexually-transmitted infections (including AIDS)
20. Contraception with intrauterine system of hormone delivery (pharmacokinetics, long-term effects, dose range, size of frame, postmenopausal use)



LIST OF POSTER BOARDS

Oral presenters

- O-01 The effects of Levonorgestrel-releasing intrauterine device (Mirena®) on adenomyosis
Chul Kim, Young Gil Moon, Young Hoon Koh
- O-02 Clinical Efficacy of Levonorgestrel-Releasing Intrauterine System(Mirena) for Contraception wanting Women with Abnormal Uterine Bleeding
Eun Chan Park, Min Hee Park
- O-03 An investigation on long-term effectiveness of "frameless GyneFix" IUD: a retrospective survey of 19301 women using "frameless" GyneFix IUD for 5 years
Hao Mingli
- O-04 Multicenter randomized controlled clinical trial of γ -IUD (memory alloy)
Liu Xiaoi*, Kang Jianzhong, Fang Aihua, Huang Zirong, Liu Yan, Cheng Licun, Fan Xiaofang, Lu Juan, Wang Yamei, Lv Yanping, Gong Juhua, Mao Xiaoyan, Zhang Wenqin, Xiao Jiang, Wang Jianhua, Xu Hong
- O-05 Continuation rates and reasons for removal among Implanon users
Hyeon Chul Kim, Suk Ho Kang
- O-06 Different risk of breast cancer due to different progestogen action? New insight on proliferative mechanism
Rong Chen¹, Hans Neubauer¹, Michael A. Cahill³, Harald Seeger¹, Markus Templin², Tanja Fehm¹, Qi Yu⁴, Alfred O. Mueck¹
- O-07 Safety aspects of dienogest in endometriosis: pooled data from a clinical development program
Faustmann T.¹, Hassall J.^{2*}, Gerlinger C.³, Seitz C.⁴
- O-08 Ethinylestradiol 20mcg/drospirenone 3mg combined oral contraceptive administered in a 24/4 regimen in the treatment of functional impairment and symptoms related to premenstrual dysphoric disorder: a randomized, multicenter, double-blind, parallel study
Joachim Marr¹, Klaas Heinemann², Michael Kunz¹
- O-09 Different risk of breast cancer due to different progestogen action? New insight on proliferative mechanism
Rong Chen¹, Hans Neubauer², Thomas Knorr³, Michael A. Cahill⁴, H. Seeger², Markus Templin³, Qi Yu¹, Tanja Fehm², Alfred O. Mueck²
- O-10 Infants outcomes after levonorgestrel-only emergency contraception failure A prospective cohort study
Zhang Lin¹, Wen Yu², Ren Fangming^{2,3}, Yang Zujing¹, Cheng Linan⁴

Abstracts

- A-01 Pelvic actinomycosis as a result of retention of intrauterine device
Chan Yong Park, Seung Ho Lee, Cheon Hoe Koo, Jong Min Park
- A-02 Mifepristone in combination with prostaglandins for termination of 10-16 weeks' gestation: a system review and meta-analysis
Chen Qiuju¹, Hou Shuping², Huang Yongmei³, Hong Qingqing⁴, Zhu Haoping⁵, Cheng Linan⁶
- A-03 Evaluate the effectiveness of a smoke evacuation system on laparoscopic surgery
C. Kim., H.Ha
- A-04 Prevalence of Chlamydia trachomatis in Singaporean Women Undergoing Termination of Pregnancy
Dharshini Gopalakrishnakone¹, Kuldip Singh²


- A-05 Asian and Caucasian women delaying motherhood by having abortions
Ellen Wiebe, Holly Yager, Amanda Chalmers
- A-06 Sexual and mood side effects of hormonal contraception in Asian and Caucasian women
Ellen Wiebe, Lori Brotto, Jacqueline MacKay
- A-07 Comparison of ovarian responsiveness and pregnancy outcomes between use of microdose GnRH agonist versus GnRH antagonist or long protocol of GnRH agonist in poor responder in in-vitro fertilization patients
Eun Joo Park, Eun Joo Choi, Won Il Park, Jin Yong Lee
- A-08 Copper level in serum and uterine tissue in pregnancy women with Cu-IUD
Yue Xiuying, Wang Xin, Guo Lina, **Gu Xiangying**
- A-09 Anti-Mullerian Hormone is a Potentially Useful Test of Ovarian Function in Progestogen-Only Contraceptive Users
Li HWR^{1,2}, Wong CYG², Yeung WSB¹, Ho PC^{1,2}, Ng EHY¹
- A-10 A retrospective study on Nova-T and Mirena
Hee Seong Ahn
- A-11 Epidemiologic Analysis of Sexual Assault Victims in Northeast Area of Seoul
Hoon Choi, Hye Young Lim, Chul Min Lee, Yong Kyoon Cho, Bok Rin Kim, Myung Whan Kim, Ji Kyung Ko
- A-12 Free Contraceptive Service for Low-socioeconomic Migrant Women: A Follow Up Study during Postpartum
Huang Yongmei, Kang Jianzhong, Hu Xiaoyu, Xiao Zhiqin, Liu Xiaoai, Cheng Linan
- A-13 The significance of cervical length at 20-24 gestational weeks in predicting preterm labor with lower risk single-tone pregnancy
HY Ahn, YH Kim, YS Yoon, JY Kwon, SJ Whang, CJ Kim
- A-14 The evaluation on effectiveness of LNG-IUS in Korea
Im Soon Lee¹, Sang Heon Cha¹, Won Yeon Jang², Jeong Jae Lee¹
- A-15 Conservative Treatment and Fertility Outcomes in Borderline Ovarian Tumors
In Ho Lee, Woo Chul Kim, Hong Jun Choi, Yong Soon Kwon, Tae Jin Kim, Ki Heon Lee, Jae Uk Shim, Jung Eun Mok, Kyung Taek Lim
- A-16 Efficacy of dienogest for the treatment of endometriosis: a comparison of two clinical trials in different ethnic populations
Gerlinger C.¹, Faustmann T.², **Hassall J.**³, Seitz C.⁴
- A-17 Rationale for assessing menorrhagia treatment modalities in the MiCo (Mirena® or conventional medical treatment for menorrhagia) study
Hassall J.
- A-18 Clinical Effects of Mirena in Uterine Adenomyosis
Jeong Yeon Kim, Young Rae Jeong
- A-19 Ethinylestradiol 20mcg/drospirenone 3mg combined oral contraceptive administered in a 24/4 regimen in the treatment of moderate acne vulgaris: primary outcomes of a pooled analysis of two randomized, double-blind, placebo-controlled studies
William Koltun¹, J. Michael Maloney², **Joachim Marr**³, Michael Kunz³
- A-20 Ethinylestradiol 20mcg/drospirenone 3mg combined oral contraceptive administered in a 24/4 regimen in the treatment of moderate acne vulgaris: secondary outcomes of a pooled analysis of two randomized, double-blind, placebo-controlled studies
William Koltun¹, J. Michael Maloney², **Joachim Marr**³, Michael Kunz³
- A-21 Contraceptive efficacy of ethinylestradiol 20mcg/drospirenone 3mg combined oral contraceptive administered in a 24/4 regimen: a pooled analysis of four, open-label studies
Leena Anttila¹, Michael Kunz², **Joachim Marr**²
- A-22 Historical cycle control comparison of ethinylestradiol 30mcg/drospirenone 3mg combined oral contraceptive

administered in a 21/7 regimen versus ethinylestradiol 20mcg/drospirenone 3mg combined oral contraceptive administered in a 24/4 regimen: a pooled analysis of two open-label, multicenter studies
M. Kunz¹, J. Marr¹, C. Gerlinger¹

- A-23 Comparative effects of estradiol valerate/dienogest and ethinylestradiol/levonorgestrel on hemostatic parameters
Christine Klipping¹, Wolfgang Junge², Uwe Mellinger³, Ingrid Duijkers¹, Andrea Machlitt⁴, Susanne Parke⁴, J. Marr⁴ (Presenter)
- A-24 Efficacy of an oral contraceptive comprising estradiol valerate/dienogest: a pooled analysis of three large trials in Europe and North America
Diana Mansour¹, Anita Nelson², Susanne Parke³, Andrea Machlitt³, Johannes Bitzer⁴, J. Marr³ (Presenter)
- A-25 Study on clinicopathological characteristics of ovarian masses
Young Mi Park¹, Jung Mi Byun², Won il Seok⁴, Young Nam Kim^{2,3}, Dae Hoon Jeong^{2,3}, Chul Hoi Jeong¹, Kyung Bok Lee², Moon Su Sung², Ki Tae Kim^{2,3}
- A-26 Addition of oral contraceptives to GnRH agonist reduce the recurrence rate of ovarian endometrioma in 36 months
Jung Ho Shin¹, Taek Hoo Lee², Byung Seok Lee³, Jun Young Hur¹, Young Min Choi⁴, Sung Tack Oh⁵, Kyu Sup Lee⁶, Yong Taik Lim⁷
- A-27 The efficacy of levonorgestrel-only emergency contraception in patients of sexual assaults
Kyung Joo Hwang, Miran Kim, Kyung Mi Lee, Dong Seok Choi
- A-28 Normal Menstrual Cycles among East Asian Immigrants in Korea; Association with Body Mass Index and Percent Body Fat
Ho Jin Cheong², Hwan Ji Kim¹, Jung Myung Kim¹, Ji Yun Kim¹, Na Yeon Kim¹, Hye Won Chung, Kyung Ah Jeong
- A-29 IUD Uterine Perforation after CS
Hanáček J., Křepelka P.
- A-30 Mifepristone induces maturation of human monocyte-derived dendritic cells
Li Li¹, Huang Lili²
- A-31 A survey on current status of family planning technical service in Baoshan District
Liu Jinglan
- A-32 The effectiveness and safety of immediate insertion of the postabortion version GyneFix IUD with Indomethacin
Liu Xiaopeng, Feng Min, Yan Chunxia, Bai Jihong, Zhang Yongping
- A-33 Evaluation of the Effectiveness of Mifepristone-misoprostol in Termination of Pregnancy
Meng Yu, Fang Aihua
- A-34 Evaluation of the effect of post-abortion counseling and education among unmarried abortion adolescents
Qin Junpu, Chen Shan, Di Na, Zhang Dikai
- A-35 Contraception and knowledge regarding a cervical Pap smear test among girls in their late teens in Korea
Sa Ra Lee¹, Si Hyun Cho²
- A-36 Hemoglobin increment after use of levonorgestrel-releasing intrauterine system
Sang Don Kim¹, Jae Hak Lee³, Byung Chul Jee^{1,2}, Joong Shin Park², Chang Suk Suh^{1,2}, Seok Hyun Kim²
- A-37 A case of pelvic Actinomyces associated with an Intrauterine Contraceptive Device
Sang Hee Lee, Su Hyun Park
- A-38 Use of the Levonorgestrel-IUS in the treatment of menorrhagia: safety and assessment of quality of life in Bombit women's Hospital
Seong Min Kim, Seong Su Kim, June Hee Lim

- A-39 The diagnostic efficacy of saline infusion sonohysterography and transvaginal sonography with abnormal uterine bleeding
Shin Seung Ju
- A-40 Efficacy and improvement of symptom of low-dose oral contraceptive in adolescents with abnormal uterine bleeding
Suk Bong Koh, Youn Seok Choi
- A-41 The association between serum estradiol level and coronary artery calcification in postmenopausal women
Sung Hoon Kim¹, Gyun Ho Jeon¹, Sung Cheol Yun², Hee Dong Chae¹, Chung Hoon Kim¹, Byung Moon Kang¹
- A-42 The effects of the intrauterine device on the sexual function of Korean reproductive age women
Sung Ho Park, Hong Bae Kim
- A-43 The study of the efficacy of low dose oral contraceptive pill in reducing premenstrual dysphoric disorder, primary dysmenorrhea and menorrhagia in Korean women
Sung Ho Park¹, Jin Sook Heo²
- A-44 Drospirenone-containing Combination Oral Pill for Treatment of Dysfunctional Uterine Bleeding
Sung Tack Oh, Moon Kyoung Cho
- A-45 The Effect of Pomegranate on Depression, Anxiety, and Food Intake in Ovariectomized Rats
Tak Kim¹, Sun Haeng Kim¹, Kyu Wan Lee¹, Byeong Sun Jeong²
- A-46 Levonorgestrel intrauterine system in the treatment of leiomyoma-related menorrhagia in a sigmoid colonic cancer patient
Vorapong Phupong, Surasak Taneepanichskul
- A-47 Analysis of the reasons related to unwanted pregnancy among women undergoing repeat induced abortion
Wen Ze, Liu Xiaoi
- A-48 A Survey on Issues against Artificial Abortion
Won Deok Joo¹, Soo Jeong Lee¹, Hyun Jin Noh¹, Ji Hye Shin², Hang Jo Yoo¹
- A-49 3 years Clinical experience with a GyneFix IUD-PP immediate post placental insertion in caesarean section women
Wu Chunzhi¹, Zheng Manhong¹, Zhang Chunlian², Xi Xiuping²
- A-50 The effects of leptin on in vitro development of mouse embryos
Yong Jin Na¹, Chang Woon Kim²
- A-51 Clinical efficacy of Levonorgestrel-releasing intrauterine system for premenopausal women need contraception
Young Jae Kim, Kyung Tai Kim, Sam Hyun Cho
- A-52 Effects of LNG-IUS on Nerve Growth Factor and its Receptors Expression in Patients with Adenomyosis
Young Sik Choi¹, Kyung Jin Im¹, Young Eun Jeon², Hyo In Yang¹, Kyung Eun Lee¹, Seok Kyo Seo², Hye Yeon Kim², Si Hyun Cho², Byung Seok Lee²
- A-53 Research of the mechanism of misoprostol for cervical softening prior to the vacuum aspiration
Zhou Juxian, Liu Xiaoi

APCOC
ASIA PACIFIC COUNCIL ON
CONTRACEPTION



INVITED SPEAKERS**Mirena® a contraceptive fit suitable for women at all stages of reproductive life**
Diana Mansour (United Kingdom)

Mirena®, the levonorgestrel-releasing intrauterine system has been hailed as one of the greatest advances in the field of contraception, since the introduction of the Pill. Over 18 million women worldwide have had Mirena® fitted with more than 10 million current users. Mirena® is a highly effective long-acting reversible contraceptive (LARC) for women of all age groups, including nulliparous women, postpartum women (including breastfeeding), during the perimenopausal period and in postabortion women. There is now evidence to suggest that copper IUDs and Mirena® can be inserted immediately after a miscarriage or first trimester termination of pregnancy without an increase in side-effects. The manufacturers recommend that the insertion of Mirena® should be delayed by about six weeks if fitted postnatally or following a second trimester abortion. This ensures the uterus is given sufficient time to regain its original involuted shape and may reduce the incidence of problematic prolonged vaginal bleeding or pelvic infection.

Very high continuation rates are found in women using Mirena® with one study reporting that 82% of women were still using it at three years. Efficacy data suggests that this system rivals female sterilisation. Unlike the latter, reversibility data showed that a woman's normal fertility will return rapidly upon removing Mirena®.

Women have chosen Mirena® not only because it is a highly effective LARC but also because it offers additional non-contraceptive benefits resulting in reduced menstrual blood loss and pain. Mirena® is licensed to provide contraception for up to five years and exerts its contraceptive action firstly, by altering the cervical mucus and uterotubal fluid which inhibits sperm migration. Secondly, Mirena® causes the uterine endometrium to atrophy by making the uterine mucosa thin, the stroma swollen, the endometrial glands atrophic and the epithelial cells inactive. Mirena® may also suppress ovulation in up to one third of cycles and possibly reduce the pre-ovulatory luteinising hormone surge.

These messages need to be conveyed to couples requesting long term, effective methods of contraception to space and limit their family size. Looking to the future, the non-contraceptive benefits of Mirena® may also improve the overall health of women.

Mirena® an alternative to surgical intervention
Si Hyun Cho (South Korea)

Currently, the only hormonal intrauterine system approved for clinical use is the levonorgestrel-releasing intrauterine system (LNG-IUS) marketed as Mirena® (Bayer Schering Pharma). It is a T-shaped plastic intrauterine device (IUD) that releases levonorgestrel

directly into the uterine cavity. Although LNG-IUS was first launched in Finland in 1990 and has been marketed in the UK since 1995 primarily as a contraceptive device, it is now used widely for its noncontraceptive effects for conditions such as heavy menstrual bleeding (HMB) and dysmenorrhea.

This system allows a steady, local release of 20 µg levonorgestrel per day, leading to a strong suppressive action on the endometrium with few systemic adverse effects. Numerous studies have shown that LNG-IUS is effective in treating HMB with reduction of menstrual blood loss (MBL) by 79–97% and with high patient satisfaction. LNG-IUS has also demonstrated a comparable increase in health-related quality of life measures and cost effectiveness in comparison to surgical treatment including hysterectomy, thermal balloon endometrial ablation and transcervical endometrial resection. It has also proven to be superior in efficacy to other medical treatment for MBL reduction in women with HMB. In 2001, LNG-IUS was licensed in the UK for HMB and the National Institute for Health and Clinical Excellence (NICE) Guideline recommended long term (at least 12-months) use of LNG-IUS as the first line pharmaceutical treatment for HMB.

In clinical applications, the main advantage of LNG-IUS in women with HMB is that it can be an effective medical option for women who are either unsuitable or reluctant candidates for surgery.

Mirena® insertion and counselling from a patient perspective
Harlina Halizah Hj Siraj (Malaysia)

Successful contraception requires a clinically effective contraceptive method together with patient adherence and acceptance to ensure continuity. In particular, contraceptive counselling to patients about side effects has been found to greatly improve patient compliance. The same principle will apply to users of the levonorgestrel-releasing intrauterine system (Mirena®). Besides proper training and insertion techniques on the providers' part, counselling is essential for overall acceptability and long-term success, since, the resultant patient empowerment leads to a natural "self selection" process where the patient herself comes to the decision to use Mirena® or not.

Investing time for full counselling, particularly in a first time user is essential to manage unrealistic expectations, explain known changes in the menstrual cycle to debunk myths and caution on possible side effects. In addition, the counselling process also reduces the likelihood of poor patient selection, which can result in unnecessarily high discontinuation rates. Health providers have to convey the biological mechanisms and major characteristics of Mirena® to patients in a way that is understandable and take into consideration individual cultural and social issues.

For first-time users of Mirena®, the changes in menstrual bleeding, spotting and possible amenorrhoea must be thoroughly explained. The patient must be

counselled to understand that reduced menstrual bleeding is not a negative effect or sign of pregnancy and that her fertility is not affected. She must be told that all these changes and effects on fertility will be rapidly reversed upon removal of Mirena®. Ideally, the clinician should inform the patient that the changes in menstrual bleeding is totally in line with the mechanism of action of Mirena® and is to be expected. Besides proper counseling, information about possible discomfort during Mirena® insertion should be conveyed. All contraindications to insertion should be ruled out. Recommended timing of Mirena® insertion is crucial, and is outlined below:

- For contraceptive use: during first seven days of cycle
- Postabortal use: immediately after operation
- Postpartum use: the earliest is after 6 weeks post partum
- Treatment of menorrhagia: on the 7th day of cycle to avoid expulsion and for ease of insertion

It is most important to learn how to insert Mirena® correctly to reduce discomfort, pain or even dislocation. A step by step insertion procedure along with proper explanation to the patient on what the healthcare provider is doing in the insertion process will help reassure the patient and improve outcomes. In addition, post insertion access to medical advice is important in case further questions arise. A follow-up visit after 3-4 months is recommended to check how well the patient is doing and for general reassurance.

How to deal with side-effects in hormonal contraception Lee Shulman (Chicago)

Hormonal contraceptives are among the most popular non-surgical methods of birth control available. However, new users of hormonal contraceptives may vary in their compliance rates, healthcare utilization, and economic and clinical outcomes. For example, many new users of oral contraceptives (OCs) discontinue their use within the first year. Commonly cited reasons for OC discontinuation include side effects and difficulty in adhering to a daily regimen. Over the past decade, hormonal contraceptive formulations that were introduced possessed features aimed at increasing convenience and compliance. Nonetheless, a critical issue for improving compliance and continuation is counseling, a process by which the woman is empowered to choose a contraceptive that she is most likely to use consistently and correctly for as long as she chooses not to be pregnant. Two relatively recent methods had nondaily schedules - the transdermal contraceptive patch containing norelgestromin and ethinyl estradiol (EE) (ORTHO EVRA®, Ortho McNeil Pharmaceutical, Inc., Raritan, NJ), which is replaced weekly for 3 weeks, followed by a patch-free week, and the vaginal contraceptive ring containing etonogestrel and EE (NuvaRing®, Organon USA, Roseland, NJ), which is worn for three weeks and replaced after a hormone-free week. Unlike other nondaily contraceptive methods, such as progestin injections and intrauterine devices, the transdermal contraceptive patch and the vaginal ring do not require a physician (other than to provide the prescription itself)

for initiation. Indeed, in the United States the use of intrauterine contraception (Mirena™; Paragard™) saw an increase for the first time in decades. However, in most parts of the world, oral contraception is the mainstay of reversible contraception. The development and use of drospirenone revolutionized our approach to oral contraception by providing a progestin with antiandrogenic and antimineralecorticoid activities. The use of extended use regimens (Seasonale™, Seasonique™, Seasonique Lo™) gave women more options if they chose to have fewer withdrawal bleeding episodes each year. In this regard, the development and use of pills with a shorter hormone-free interval - specifically a 24/4 regimen (Yaz™ and LoEstrin 24/4™) provided women who wished to have a monthly withdrawal bleed with more options and, in the case of Yaz™, novel noncontraceptive effects. Finally, the recent release of the E2V/DNG pill regimen (Qlara™) represents a totally new approach to contraception and lifestyle considerations. While the contraceptive choices for women have increased, we must remain vigilant in ensuring that women have the necessary information to make informed decisions about their reproductive activities - for she is the person who knows best what is right for her. In this way, better choices will be made, more effective counseling can be provided and consistent and correct use will increase, with the concomitant drop in adverse events and dissatisfied women using less effective methods and exposing themselves to higher rates of unintended pregnancy and its associated morbidity and mortality.

Speaker Biography

Lee P. Shulman MD FACMG FACOG

Lee P. Shulman MD is the Anna Ross Lapham Professor in Obstetrics and Gynecology and Chief of the Division of Clinical Genetics at the Feinberg School of Medicine at Northwestern University in Chicago, Illinois. He also serves as the Director of the Cancer Genetics Program of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Co-Director of the Northwestern Ovarian Cancer Early Detection and Prevention Program. Dr. Shulman is an Adjunct Professor in the Department of Medicinal Chemistry and Pharmacognosy at the University of Illinois at Chicago College of Pharmacy. He is a Fellow of the American College of Obstetricians and Gynecologists and a Founding Fellow of the American College of Medical Genetics. Dr. Shulman was graduated from Cornell University in 1979 with a BA degree in the College Scholar program. He then attended Cornell University Medical College where he received his Doctor of Medicine degree in 1983. Dr. Shulman completed an internship and residency in Obstetrics and Gynecology at North Shore University Hospital - Cornell University Medical College in 1987 and served as Chief Resident during his final year. From there he completed a fellowship in Reproductive Genetics at the University of Tennessee, Memphis and then joined the Ob/Gyn faculty of the University of Tennessee, Memphis, becoming the Director of Reproductive Genetics in 1994. In 1999 he relocated to the University of Illinois at Chicago where he served as Deputy Head of the Department of Obstetrics and Gynecology, Director of the Divisions of Reproductive Genetics and Ambulatory Care Services and as Medical Director

of the Center of Excellence in Women's Health. Dr. Shulman is a member of numerous regional, national and international organizations that pertain to the health and care of women. He currently serves as the Immediate Past Chair of the Board of Trustees of the Association of Reproductive Health Professionals. His work has been recognized regionally and nationally; most recently, he was included in the list of "Top Doctors" in Chicago (2007-8) and the United States (2010). He is the Editor-in-Chief of the Yearbook of Obstetrics and Gynecology and Reproductive Medicine, is a Contributing Editor for The Journal of Reproductive Medicine and the Executive Editor of the Journal of Gynecologic Surgery. He also serves on the editorial boards of Prenatal Diagnosis, Journal of Pediatric and Adolescent Gynecology, Contraception, Menopause, and as a peer-reviewer for 34 journals.

What are the ways to encourage compliance Christine Read (Sydney)

Compliance is an essential element in maintaining efficacy with contraceptive methods that are easily reversible by the consumer, such as the condom and the combined oral contraceptive pill. As healthcare professionals it is vital that we recognize and mitigate risks for poor compliance when prescribing contraceptive methods. It is important to provide information and counseling so that the patient's unique needs can be taken into consideration and that she is fully informed and consents to use of the method proposed. At a minimum we should also provide information on the following at the consultation; how to use the method prescribed by demonstrating how to start taking pills, discuss what to expect (side effects, bleeding patterns etc), what to do if things go wrong e.g. missed pills, broken condom and where to find more information (consumer product information, telephone and web based information services).

Speaker Biography

MBBS, ThA, FACHSHM, Grad Cert PH
Dr Read is an independent consultant in Family Planning and Reproductive and Sexual Health. Until April 2010 she was the Medical Director of Family Planning NSW. She trained as a sexual health physician and has a particular interest in the use of contraceptive methods and the issue of unplanned pregnancy. She has managed a number of innovative projects to address the lack of services and information in these areas for Australian rural and Aboriginal women. Dr Read has also worked in the areas of menopause and mid life for many years and is Honorary Secretary of the Australasian Menopause Society. Dr Read is an investigator for a number of research projects including an international contraceptive study, has published original research in peer reviewed journals and edited a number of medical handbooks including 'Contraception: an Australian clinical practice handbook' and 'The Vulva: A Clinician's Practical Handbook.'

How to increase access to contraceptive use – a low-cost implant
Marcus Steiner (FHI, USA), Diane Luo,

Aida M. Cancel, David Jenkins, David Asante, Heather Vahdat, Haizhen Meng

Background: Contraceptive implants were introduced more than 25 years ago with the promise of offering women a highly effective method that does not require user maintenance (e.g., the correct and consistent use of condoms, daily taking of pills, etc). However, demand for this contraceptive method far outstrips available supply because a high up-front per-unit commodity cost prohibits sustainable provision by donors. Sino-implant (II) is a two-rod, levonorgestrel-releasing implant at about 60 percent lower cost than other widely available implants.

Methods: This five year project will help the manufacturer: 1) ensure the continued quality of Sino-implant (II); 2) obtain regulatory approvals in at least 14 countries and have Sino-implant (II) prequalified by the World Health Organization (WHO); and 3) coordinate and evaluate introduction and sustainable program activities in select countries where Sino-implant (II) is registered to ensure successful scale-up.

Results: We will present the clinical and laboratory evaluations conducted in the past two years demonstrating Sino-implant (II) meets international quality standards. This initiative has helped with product approval in 5 countries (Kenya, Sierra Leone, Madagascar, Malawi and Zambia). Dossiers are under review with national drug authorities in 10 additional countries. We are actively working with service delivery partners in countries where the product is registered with product launch meetings, training and evaluation. **Conclusion:** Introducing Sino-implant (II) into programs in a well-coordinated manner will lead to substantial cost-savings for governments and donors. In the first year of the project, 112,200 units have been distributed resulting in cost-savings of well over US\$ 1 million.

Speaker Biography

Markus J. Steiner, PhD, MSPH, a Senior Epidemiologist, has worked at Family Health International for the past 20 years focusing on barrier method acceptability and contraceptive effectiveness trials. Most recently, he is spearheading an initiative to ensure the quality of a generic contraceptive implant (Sino-implant) and proceeding with global registrations, including WHO prequalification. He has extensive experience conducting research around the world (Brazil, Cameroon, Chile, China, Ethiopia, Ghana, Hungary, India, Jamaica, Kenya, Ghana, Malawi, Sri Lanka, Thailand, The Dominican Republic, Turkey, Zimbabwe). He has published over 65 peer-reviewed articles and serves as an ad hoc reviewer for scientific journals including JAMA, American Journal of Public Health, Sexually Transmitted Diseases and Obstetrics & Gynecology. In 2001 he was named adjunct assistant professor in the Department of Epidemiology, School of Public Health, University of North Carolina at Chapel Hill, where he received his PhD in reproductive epidemiology.

What is new in contraception use. New products: now and the future